Mitchell Shirvan
CIK 1727789 · CSO and CDO · last filed 2026-06-08
Mitchell Shirvan is a CSO and CDO who has filed 5 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for SLXNW, was dated Jun 8, 2026. Across all open-market trades the lifetime net is −$31.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $221 across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$221
2
5
-$31.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SLXNW | CSO and CDO | 8,789 | $0.03 | $221 | -$31.0K | 3 | 2026-06-08 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | VP Innovation & Discovery | 24,980 | — | — | $0 | 2 | 2018-02-28 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-08 | SLXNW | Grant (A) | +6,000 | $0 | EDGAR |
| 2026-03-30 | SLXNW | Sell (S) | −22,818 | -$31.0K | EDGAR |
| 2026-02-23 | SLXNW | Grant (A) | +49,726 | $0 | EDGAR |
| 2018-02-28 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2018-01-24 | Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Exer (M) | +3,307 | $0 | EDGAR |